Celcuity (CELC) Projected to Announce Earnings on Thursday

Celcuity (NASDAQ:CELC) is anticipated to release its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Celcuity to post earnings of ($1.16) per share and revenue of $4.42 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. On average, analysts expect Celcuity to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Celcuity Stock Performance

NASDAQ:CELC opened at $92.92 on Thursday. The stock has a 50-day moving average price of $96.13 and a 200 day moving average price of $109.29. The stock has a market capitalization of $4.53 billion, a P/E ratio of -23.83 and a beta of 0.20. Celcuity has a 12-month low of $42.38 and a 12-month high of $151.02. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04.

Analyst Ratings Changes

Several research analysts have weighed in on CELC shares. Guggenheim restated a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Needham & Company LLC reiterated a “buy” rating and set a $157.00 price objective on shares of Celcuity in a research report on Friday, May 15th. Citigroup reissued an “outperform” rating on shares of Celcuity in a report on Wednesday, July 15th. Macquarie Infrastructure set a $160.00 target price on shares of Celcuity in a report on Thursday, May 28th. Finally, Leerink Partners set a $155.00 target price on shares of Celcuity in a research report on Tuesday, June 2nd. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Celcuity has an average rating of “Moderate Buy” and a consensus price target of $155.18.

Institutional Trading of Celcuity

A number of large investors have recently added to or reduced their stakes in the company. US Bancorp DE increased its stake in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the last quarter. Aristides Capital LLC raised its position in Celcuity by 2.0% during the fourth quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock valued at $1,526,000 after purchasing an additional 303 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Celcuity by 4.2% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 8,637 shares of the company’s stock valued at $861,000 after purchasing an additional 350 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Celcuity in the 4th quarter valued at approximately $42,000. Finally, Rhumbline Advisers boosted its holdings in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after purchasing an additional 503 shares during the period. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.